C4b-Binding Protein (C4BP) Activates B Cells through the CD40 Receptor  by Brodeur, Scott R. et al.
Immunity, Vol. 18, 837–848, June, 2003, Copyright 2003 by Cell Press
C4b-Binding Protein (C4BP) Activates B Cells
through the CD40 Receptor
CD40L interaction is critically important as isotype
switching is severely impaired in patients with CD40L
(HIGM-1) and CD40 gene mutations (HIGM-3) (Ferrari et
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importance of p38 in CD40-mediated CSR is illustrated
by the block of CD40IL-4 induced isotype switchingSummary
to IgE by the p38 inhibitor SB203580 (Brady et al., 2001;
Zhang et al., 2002).We demonstrate that thechain of human C4b binding
C4b binding protein (C4BP) is a regulatory componentprotein (C4BP) binds directly to CD40 on human B cells
of the classical complement pathway that is synthesizedat a site that differs from that used by CD40 ligand.
by liver cells and activated monocytes (Kusada-Funa-C4BP induces proliferation, upregulation of CD54 and
koshi et al., 1991; Lappin and Whaley, 1990) and isCD86 expression, and IL4-dependent IgE isotype
upregulated by glucocorticoids and inflammatory cyto-switching in normal B cells but not in B cells from
kines (IFN-, IL-1, Il-6, and TNF-) (Lappin and Whaley,patients with CD40 or IKK/NEMO deficiencies. Fur-
1990; Moffat and Tack, 1992). C4BP is a functional co-
thermore, C4BP colocalized with B cells in the germi-
factor for Factor I-dependent degradation of C4b and
nal centers of human tonsils. These observations sug- C3b (Blom et al., 2003; Dahlback and Hildebrand, 1983)
gest that C4BP is an activating ligand for CD40 and and accelerates decay of C3-convertase (Gigli et al.,
establish a novel interface between complement and 1979). C4BP circulates in human plasma in three iso-
B cell activation. forms based upon different combinations of  (70 kDa)
and  (45 kDa) chains (Hillarp et al., 1989). The predomi-
Introduction nant isoform contains seven  chains and one  chain
(71) covalently linked by disulfide bonds at the C
CD40 is a member of the tumor necrosis factor (TNF) terminus (Kask et al., 2002; Pardo-Manuel et al., 1990).
receptor superfamily expressed on the surface of B cells Two minor isoforms consist of 70 and 61 (Criado
(Banchereau et al., 1994a). Engagement of CD40 with Garcia et al., 1995). The C4BP chain contains eight
its ligand, CD154 (CD40L), results in proliferation, upreg- complement control protein (CCP) domains at its N ter-
ulation of CD54 and CD86, and rescue of germinal center minus and a unique 58 amino acid C-terminal core region
B cells from apoptosis (Calderhead et al., 2000). In addi- critical for multimerization. The three N-terminal CCPs
tion, CD40 ligation, in the presence of the cytokines on the C4BP chain contain the binding site for C4b
interleukin 4 (IL-4) or IL-13, induces immunoglobulin iso- (Blom et al., 2001a) that is independent of C4BP (Ogata
type switching to IgE (Oettgen and Geha, 1999). CD40- et al., 1993). C4BP also has binding sites for heparin
(Hessing et al., 1990), some bacterial proteins (Johnsson
et al., 1996; Berggard et al., 1997; Blom et al., 2001b),*Correspondence: geha@a1.tch.harvard.edu
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and serum amyloid protein (SAP) (Schwalbe et al., 1990).
The C4BP-chain binds the Protein S anticoagulant (Hil-
larp and Dahlback, 1988).
We have previously described a 23 kDa protein (p23)
that is associated with the extracellular domain of CD40
but not with other members of the TNFR family (Morio et
al., 1995). Here, we show that amino acid (aa) sequences
derived from p23 are homologous to aa sequences in
human C4BP and that C4BP binds directly to CD40 on
human B cells and activates them in a manner similar
to CD40L. These findings suggest that C4BP may pro-
vide an alternative pathway for activating B cells through
the CD40 receptor.
Results
C4BP Binds Directly to CD40 via the C4BP Chain
We previously reported the association of the p23 pro-
tein with the extracellular domain of CD40 from human
B cell lines grown in fetal calf serum (FCS) (Morio et al.,
1995). Three internal peptides from p23 of 17, 11, and 7
aa were purified and sequenced. The 11-aa-long peptide
was entirely contained within the 17-aa-long peptide.
Homology searches using the SwissProt database re-
vealed the 17 and 7 aa peptides from p23 are homolo-
gous to sequences contained in CCP8 and the core
region of human (hu) C4BP (Figure 1A). The p23 pep-
tides show no homology to sequences in huC4BP (data
not shown).
To investigate the origin of p23, we used rabbit antise-
rum raised against the 17 aa peptide of p23 to specifi-
cally recognize a 23 kDa protein in CD40 immunoprecipi-
tates but not in MHC class II immunoprecipitates, from
human BJAB cell lysates grown in FCS (Figure 1B). In
contrast, the same antiserum failed to detect a 23 kDa
band in CD40 immunoprecipitates from BJAB cells
Figure 1. C4BP Is Homologous to p23 and Binds to CD40grown in human serum. These results suggested that
(A) Amino acid sequence comparison of two internal peptides fromp23 is of bovine origin. This was supported by the obser-
p23 and human (hu) C4BP .vation that the anti-p23 antiserum recognized a 23 kDa
(B) Detection of p23 in CD40 immunoprecipitates from BJAB cell
protein only in FCS but not in human serum (data not lysates of cells grown in either FCS or human serum (HS). Anti-
shown). CD40 (626.1) or anti-MHC class II (3B12) immunoprecipitates were
Given the partial homology between p23 and C4BP Western blotted and probed with anti-p23 (upper panel) or with anti-
CD40 (lower panel). Results are representative of three experiments.sequences, we examined whether C4BP displaces the
(C) C4BP competes with p23 for CD40 binding on the surface ofbinding of p23 to CD40. BJAB cells grown in FCS were
BJAB cells. Anti-CD40 or MOPC21 immunoprecipitates of BJAB cellpreincubated with C4BP for 1 hr and lysed, and CD40 lysates (grown in FCS) with or without the addition of 20 g/ml of
immunoprecipitates were examined for the presence of HuC4BP71 were Western blotted and probed with anti-p23 (upper
p23. Exogenous C4BP displaced p23 binding to CD40 panel) or with anti-CD40 (lower panel). Results are representative
of three experiments.(Figure 1C), suggesting that C4BP bind CD40 at a site
(D) C4BP binds directly to CD40. C4BP6 (left panel) andthat overlaps that used by p23.
C4BP71 (right panel) were precipitated with protein G-SepharoseWe next investigated whether huC4BP interacts di-
beads (Medium), beads coupled to CD40:Ig or murine IgG2a (mIgG).
rectly with CD40. Purified huC4BP6 was mixed with Samples were Western blotted with rabbit anti-C4BP. Results are
Sepharose-G beads coated with recombinant CD40:Ig representative of two experiments.
fusion protein or with control isotype-matched muIgG.
Figure 1D (left panel) shows that C4BP binds to
CD40:Ig coated beads. Since C4BP exists predomi- C4BP Binds Specifically to CD40 on Human B Cells
nantly in the 7 1 isoform (Hillarp et al., 1989), we also at a Site that Differs from CD40L
examined the binding of this isoform to CD40. Figure We tested the capacity of huC4BP71, which will sub-
1D (right panel) shows that huC4BP71 also binds to sequently be termed C4BP, to bind to CD40 expressed
CD40:Ig coated beads, but not with muIgG beads on the surface of B cells. C4BP binding was analyzed by
coated. These results suggest that C4BP binds directly flow cytometry using biotinylated C4BP or biotinylated
-galactosidase, as a negative control, followed byto CD40 via its  chain.
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streptavidin-PE (SA-PE). C4BP, but not -galactosidase,
binds to the human B cell lines BJAB, Ramos, Daudi,
and Raji, which express CD40 (Figure 2A). In contrast,
there was no detectable binding of C4BP to the human
T cell lines Jurkat 6.1 and HUT-78, which do not express
CD40.
B cell lines may not be representative of normal B
cells. Therefore, it was important to examine whether
C4BP binds to normal resting B cells. PBMCs were dou-
ble-stained with CD19-FITC and biotinylated C4BPSA-
PE. C4BP bound to virtually all CD19 positive cells in
blood and tonsils (Figure 2B) but did not bind to CD19
cells (Figure 1B) or to CD3 cells (data not shown).
To determine whether C4BP binding to B cells was
dependent on CD40, we examined C4BP binding to
EBV-transformed B cells from a CD40-deficient patient.
This patient has a mutation of the CD40 gene resulting
in a frameshift, that abolishes exon 5 and CD40 surface
expression on peripheral blood B cells (Ferrari et al.,
2001). Figure 2C (upper panel) shows that, in contrast
to EBV-transformed B cells from a normal control, the
patient completely failed to express CD40 on their sur-
face. More importantly, biotinylated C4BP bound to nor-
mal B cells but completely failed to bind to the patient’s
B cells (Figure 2C, lower panel). These results suggest
that C4BP specifically binds CD40 on human B cells.
To determine if the C4BP and CD40L binding sites on
CD40 are distinct, we examined whether C4BP com-
petes with CD40L for binding to CD40. CD40L binding
was assessed by FACS analysis of BJAB cells incubated
with 1 g/ml biotinylated CD40L:muCD8 SA-PE. Fig-
ure 2D shows that, as expected, 20 g/ml of unlabeled
CD40L inhibited the binding of biotinylated CD40L to
the B cells. In contrast, 20 g/ml of unlabeled C4BP or
control protein, human IgM (hIgM), failed to inhibit the
binding of biotinylated CD40L. Similarly, unlabeled
C4BP inhibited the binding of biotinylated C4BP to BJAB
cells, but neither CD40L:muCD8 nor hIgM was able to
displace the binding of biotinylated C4BP (Figure 2E).
These results suggest that C4BP and CD40L bind to
distinct sites on CD40.
C4BP Induces B Cell Proliferation
CD40 ligation causes B cell proliferation (Banchereau
et al., 1994b). Since C4BP exists as a multimer that
contains 6 or 7 C4BP chains, it is likely that it crosslinks
CD40. This may result in activation of CD40 signaling.
Stimulation with C4BP for 4 days indeed induced prolif-
eration of purified human B cells in a dose dependent
manner (Figures 3A and 3B).
B cells can be induced to express CD40L (Grammer
et al., 1995; Jabara et al., 2001). C4BP failed to induceFigure 2. C4BP Binds to CD40 on B Cells at a Site Distinct from
detectable CD40L mRNA expression in B cells fromCD40L
healthy controls (data not shown). To rule out the possi-(A) FACS analysis of the binding of biotinylated C4BP (solid line) or
biotinylated -galactosidase (dashed line) SA-PE to B cell and
T cell lines. Results are representative of two experiments.
(B) FACS analysis of the binding of biotinylated C4BP to peripheral
blood and tonsil cells using double immunofluorescence with anti- (D and E) C4BP and CD40L do not compete with CD40L for binding
CD19 FITC. Results are representative of three experiments. to B cells. BJAB cells were directly stained with 1 g/ml biotinylated
(C) C4BP and anti-CD40 fail to bind to B cells from a CD40-deficient CD40L:mCD8 (D) or 20 g/ml biotinylated C4BP (E) SA-PE (green
patient. FACS analysis of the binding of biotinylated C4BPSA-PE peaks), or were stained with these reagents following preincubation
(lower panels) and PE-conjugated anti-CD40 (upper panels) to EBV- with 20 g/ml (in [D]) or 100 g/ml (in [E]) of human IgM (hIgM, blue),
transformed B cells from a CD40-deficient patient and normal CD40L:CD8 (orange), or C4BP (purple). The red peaks represent
control. control staining with SA-PE alone.
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similar extent as control PBMCs (9,640 or 144,420 cpm,
respectively).
CD40-mediated proliferation of B cells is dependent
on IKK/NEMO (Doffinger et al., 2001; Jain et al., 2001).
We examined the response of B cells from two HED-ID
patients with point mutations in IKK/NEMO. B cells
from both of these patients fail to undergo IgE-mediated
isotype switching in response to sCD40LIL-4 (Orange
et al., 2002). PBMCs from these patients also failed to
proliferate to C4BP (Figure 3D). This was not due to a
generalized defect in these cells as they proliferated
normally to IL4 or PHA (16,480 and 146,450 cpm, respec-
tively, for IKK/NEMO #1 and 10,450 and 137,325 cpm,
respectively, for IKK/NEMO #2, compared to 13,570
and 194,210 cpm, respectively, for a normal control).
These results suggest C4BP signals directly via CD40
and requires the IKK complex to induce B cell prolifer-
ation.
C4BP Induces Upregulation of CD54 and CD86
Expression on B Cells
CD40 ligation causes the upregulation of surface ex-
pression of a number of markers on B cells that include
CD54 and CD86 (Banchereau et al., 1994a). Stimulation
of normal B cells with C4BP for 36 hr resulted in the
upregulation of CD54 and CD86 surface expression (Fig-
ure 4). Upregulation of CD54 by C4BP was consistently
weaker than that observed with CD40L (MFI for B cells
stimulated with medium, C4BP, or CD40L: 34, 92, and
228, respectively, n	 3). Upregulation of CD86 by C4BP
was equivalent to that observed with CD40L (MFI for B
cells stimulated with medium, C4BP, or CD40L: 21, 103,
and 178, respectively, n 	 3).
C4BP upregulated CD54 and CD86 surface expres-
sion normally in B cells from the CD40L-deficient pa-
tients but failed to upregulate the expression of these
two markers in B cells from CD40-deficient and IKK/
Figure 3. C4BP Induces B Cell Proliferation NEMO patients (Figure 4). B cells from the IKK/NEMO
Proliferation of B cells from normal controls (A) with its dose re- patients also failed to upregulate CD86 and upregulated
sponse (B) and of PBMCs from patients with mutations in CD40L
CD54 expression poorly in response to CD40L.(C), CD40 (C), and IKK/NEMO (D) in response to C4BP. B cells or
PBMCs were cultured with medium, C4BP, sCD40L, or both, fol-
lowed by the assessment of 3H-thymidine incorporation into DNA. C4BP and IL-4 Induce IgE Synthesis in B Cells
Results are representative of two to three independent experiments. CD40 ligation synergizes with IL-4 in causing isotype
switching to IgE (Jabara et al., 1990). Stimulation with
C4BPIL4 for 14 days induced IgE synthesis in purified
human B cells that was equivalent to sCD40LIL4 in-bility that the effect of C4BP on B cell proliferation was
mediated via induction of CD40L, we examined the re- duction (Figure 5A). Induction of IgE synthesis by
C4BPIL-4 was independent of CD40L becausesponse of B cells derived from two HIGM-1 patients
with mutations in CD40L. In one patient (CD40L#1), the C4BPIL-4 induced IgE synthesis in PBMCs from
CD40L-deficient patients (Figure 5B). However, it wasmutation abolished CD40L surface expression, and, in
the other (CD40L#2), it abolished CD40 binding to the dependent on CD40 and IKK/NEMO, because
C4BPIL-4 failed to induce IgE synthesis in PBMCsexpressed CD40L (Chu et al., 1995; Ramesh et al., 1993).
PBMCs from the two CD40L-deficient patients prolifer- from CD40-deficient patients and HED-ID patients with
IKK/NEMO mutations (Figure 5B). These patients alsoated in response to C4BP to an extent similar to that of
control B cells (Figure 3C). fail to produce IgE in response to sCD40LIL-4. CD40-
deficient B cells produced IgE in response to the CD40-To ascertain that the proliferative response to C4BP
was dependent on CD40 expression, we examined the independent stimulus, EBVIL4 (18,030 pg/ml, com-
pared to the normal control at 3,210 pg/ml). B cells fromresponse of PBMCs from a CD40-deficient patient. This
patient failed to proliferate to CD40L (Figure 3C), but HED-ID patient samples did not produce IgE in response
to EBVIL-4 (data not shown).more importantly, they failed to proliferate to C4BP. This
was not due to a generalized defect in these cells, be- CD40 ligation synergizes with IL-4 to induce the ex-
pression of C GLT and AID and to cause S→S dele-cause PBMCs from this patient proliferated to EBV infec-
tion or PHA (7,700 and 107,270 cpm, respectively) to a tional switch recombination that results in CSR to IgE
B Cell Activation by C4BP
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Figure 4. Upregulation of CD54 and CD86
Expression on B Cells by C4BP
PBMCs or B cells were stimulated 36 hr with
medium (red), C4BP (blue), or purified sCD40L
(green) costained with anti-CD20-PE and
FITC-conjugated CD54 or CD86. Gated CD20
positive cells are shown. Isotype controls
after stimulation with either CD40L or C4BP
were not shifted (data not shown). Results are
representative of two to three independent
experiments.
(Manis et al., 2002). The ability of C4BP and sCD40L, human (Golay et al., 1992; Lee et al., 1999; Sarma et al.,
1995) and mouse B cells (Dadgostar et al., 2002). Liga-as positive control, to synergize with IL-4 in activating
these molecular events was examined in normal purified tion of CD40 with sCD40L-upregulated bcl-xL, A20, and
c-myc expression in normal B cells (Figure 6C) and nor-B cells. As previously reported, IL-4 but not sCD40L
induced C GLT in B cells after 3 days in culture, and mal PBMCs (Figure 6D) but not in PBMCs from a patient
with an IKK/NEMO mutation (Figure 6D). Loss of upreg-the two stimuli synergized in the induction of C GLT
expression (Jabara et al., 1990). C4BP also did not in- ulation with the IKK/NEMO mutants confirms that CD40
upregulation of these three genes in normal human Bduce C GLT by itself, but synergized with IL-4 in induc-
ing C GLT in B cells (Figure 6A). cells is NFB dependent. C4BP, like sCD40L, upregu-
lated bcl-xL, A20, and c-myc gene expression in normalAID plays an essential role in CSR (Muramatsu et al.,
2000; Revy et al., 2000). AID expression was induced PBMCs and B cells (Figure 6C) but not in PBMCs from
the patients with IKK/NEMO mutations (Figure 6D). Weafter 3 days in normal B cells by IL4. sCD40L poorly
induced AID but strongly synergized with IL-4 in induc- also directly examined whether C4BP causes nuclear
translocation of NFB using electrophoretic mobilitying AID mRNA expression. C4BP by itself induced AID
expression, and it strongly synergized with IL-4 in B shift assay (EMSA) analysis. C4BP stimulation caused
nuclear translocation of NFB in normal B cells but notcells (Figure 6A).
We used DC-PCR to assess deletional S→S switch in B cells from a patient with a mutation in IKK/NEMO
(Figure 6E). These results suggest that NFB is activatedrecombination in purified B cells. As expected, sCD40L
synergized with IL-4 in causing S→S deletional switch by C4BP in B cells.
CD40 ligation in B cells activates the MAP kinaserecombination (Figure 6B). C4BP, also synergized with
IL-4 in inducing deletional S→S switch recombination p38, which plays an important role in CD40-driven CSR
(Aicher et al., 1999). p38 has been shown to mediate(Figure 6B). CD40L, C4BP, and IL4 did not induce these
events by themselves. CD40 downregulation of expression of a number of
genes that include diacylglycerol kinase (DAG kinase
) and p38 in murine B cells (Dadgostar et al., 2002).Regulation of NFB- and p38-Dependent Genes
by C4BP in B Cells We examined the effect of C4BP on the expression of
these two genes as an indirect means to determineNFB activation plays a critical role in CD40 signaling
in B cells. CD40 ligation causes NFB-dependent upreg- whether C4BP activates p38 in B cells. p38 and DAG
kinase gene expression was downregulated byulation of bcl-xL, A20, and c-myc gene expression in
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markers CD19 and CD40 (Figure 7A). Anti-C4BP did not
stain extrafollicular T cell-rich areas that stained positive
with CD3 (Figure 7A). Staining with rabbit IgG anti-C4BP
was specific because preincubation of the anti-C4BP
antibody with C4BP abolished its ability to stain tonsillar
tissue. Germinal centers were detected by peanut agglu-
tinin (PNA) staining (Figure 7B). C4BP colocalized to the
PNA areas of the tonsil tissue. These results suggest
that C4BP may interact with CD40 in B cells in the germi-
nal centers of secondary lymphoid follicles.
Discussion
We demonstrate that the complement regulatory protein
C4BP binds to CD40 and mimics B cell activation in-
duced by CD40L. These findings suggest a novel inter-
face between the complement system and B cell acti-
vation.
Our investigation of C4BP binding to CD40 was
prompted by the aa sequence homology between
C4BP and p23, a 23 kDa protein that coprecipitates
with CD40 from BJAB cells grown in FCS (Figure 1A).
Our results indicate that p23 is of bovine origin, because
p23 coprecipitated with CD40 from lysates of B cells
grown in FCS but not in human serum (Figure 1) as
detected with anti-p23 peptide antibody. The exact na-
ture of p23 remains unknown as the p23 sequences are
not completely conserved in bovine C4BP. The two
peptide sequences derived from p23 also show homol-
ogy to sequences in pig apolipoprotein R (apoR), a 23
kDa protein of unknown function found in pig plasma.
The cDNA for apoR shows 67% identity with the human
C4BP cDNA region encoding CCP7, CCP8, and the
C-terminal core region (Cooper and Attie, 1992). The aa
sequences in human C4BP with homology to the two
Figure 5. Induction of IgE Synthesis in B Cells by C4BPIL-4
identified sequences for p23 are also located in the
(A) Net IgE synthesis by B cells from normal controls (A) and patients CCP8 and core region of human C4BP.with mutations in CD40L (B), CD40 (B), and IKK/NEMO (C) in re-
Our data suggest that human C4BP binds directly tosponse to C4BPIL-4. B cells were cultured for with medium, IL-4,
CD40. Pull-down assays demonstrated that the C4BP6C4BPIL-4, and sCD40LIL-4. IgE values in supernatants of un-
stimulated cells were 
3.75 ng/ml and were subtracted from values chain, as well as C4BP71, interact directly with the
of stimulated cultures. The asterisk indicates undetectable IgE syn- extracellular domain of CD40 (Figure 1C). This suggests
thesis (
3.75 ng/ml). There was no detectable IgE synthesis in B cell that the C4BP chain is sufficient for CD40 binding and
cultures stimulated with C4BP or sCD40L alone (data not shown). is preserved in C4BP71. C4BP binds to human CD40Results are representative of two to three independent experiments.
on B cells as C4BP was shown to bind to CD40 human
B cell lines and to freshly isolated human B cells but
fails to bind to CD40 human T cell lines or to freshlysCD40L in human B cells and was blocked by the spe-
cific p38 inhibitor SB203580 (Figure 6F). These results isolated T cells (Figures 2A and 2B). The CD40 specificity
of C4BP binding to B cells was established by the obser-indicate that CD40 downregulation of DAG kinase and
p38 expression in human B cells, as in mouse B cells, vation that C4BP failed to bind to B cells from a CD40-
deficient patient (Figure 2C).is dependent on p38. C4BP, like sCD40L, downregulated
DAG kinase and p38 expression, and this was also C4BP and CD40L failed to compete with each other
for binding to B cells (Figure 2D), suggesting that theyinhibited by SB203580 (Figure 6F). These results sug-
gest that C4BP activates the MAP kinase p38 in B cells. bind to distinct sites on CD40. C4BP mimicked CD40L
in causing B cell activation by inducing proliferation,
upregulation of CD54 and CD86 surface expression, andC4BP Colocalizes with B Cells in Human Tonsils
B cell activation including isotype switching occurs in induction of IgE synthesis in the presence of IL-4 (Fig-
ures 3–5). The fact that C4BP induced B cell activationgerminal centers (Banchereau et al., 1994a; Liu et al.,
1996). It was therefore important to determine whether in the presence of FCS, which contains p23, is consis-
tent with the observation that C4BP displaces p23 bind-C4BP colocalizes with B cells in lymphoid tissues. Se-
quential sections of human tonsillar tissue were stained ing to CD40 on cells (Figure 1C). p23 was not necessary
for activation of the B cells by C4BP. C4BP activated Bfor C4BP and individual B and T cell antigens using
immunoperoxidase. Anti-C4BP stained secondary folli- cells that were cultured in 10% heat inactivated serum
obtained from a patient with X-linked agammaglobuli-cles (Figures 7A and 7B) and colocalized with the B cell
B Cell Activation by C4BP
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Figure 6. Molecular Events in IgE Isotype
Switching Induced by C4BPIL-4
(A) Expression of C germline and AID tran-
scripts measured by RT-PCR in B cells stimu-
lated for 72 hr with medium, IL-4, C4BP,
CD40L, C4BPIL-4, and CD40LIL-4.
GAPDH transcripts were measured to indi-
cate equivalent amounts of cDNA and to de-
termine the linear range of the RT-PCR reac-
tions.
(B) S→S deletional switch recombination
(CDC-PCR) measured by DC-PCR. The
-globin DC-PCR confirms circularization of
the genomic DNA.
(C, D, and F) Upregulation of bcl-xL, A20, and
c-myc mRNA expression (C and D) and down-
regulation of DAG kinase  (DAGK ) and p38
mRNA expression (F) by C4BP. PBMCs or B
cells were stimulated with C4BP or CD40L
for 6–12 hr. Similar results were obtained with
both patients with mutation in IKK/NEMO.
The p38 inhibitor SB203580 was added 1 hr
before stimulation with C4BP and CD40L.
mRNA expression was examine by gene spe-
cific RT-PCR. GAPDH transcripts were mea-
sured to indicate equivalent amounts of
cDNA and to determine the linear range of
the RT-PCR reactions.
(E) C4BP causes translocation of NFB com-
plexes to the nucleus. Nuclear extracts from
unstimulated (medium) and C4BP stimulated
PBMCs from control or HED-ID patients with
mutations in IKK/NEMO were analyzed by
EMSA. The results in (A) through (F) are repre-
sentative of at least two independent experi-
ments.
nemia. This serum, which did not contain detectable This is supported by the observation that C4BPIL-4
induced IgE isotype switching in B cells from CD40L-p23 or IgE, supported C4BP-induced proliferation,
upregulation of CD54 and CD86 surface expression, and deficient patients who lack detectable serum IgE (Figure
5B). Further evidence that induction of IgE synthesis byinduction of IgE synthesis in the presence of IL-4 to an
extent similar to FCS (see Supplemental Figure S1 C4BPIL-4 represented isotype switching was provided
by examination of molecular events that are required[http://www.immunity.com/cgi/content/full/18/6/837/
DC1]). The fact that C4BP, which binds to a distinct site for deletional switch recombination. C4BP synergized
with IL-4 to induce the expression of CGLT and inducedon CD40 from CD40L, activates B cells is consistent
with the observation that select mAbs that do not inhibit AID. In contrast to CD40L, C4BP alone upregulated AID
expression. A difference in the effect of CD40L andCD40L binding can deliver an activation signal to B cells
(Challa et al., 1999). Furthermore, it suggests that C4BP C4BP on CD54 upregulation was also noted. These dif-
ferences could represent a difference in the strengthand CD40L may deliver additive signals to the B cells.
In fact, using a single concentration for each ligand, we and/or quality of the signal generated by the two ligands.
More importantly, C4BPIL-4 caused S→S deletionalhave often observed an additive effect of C4BP and
CD40L on B cell proliferation (Figure 3A). switch recombination as assessed by DC-PCR (Figures
6A and 6B).Activation of B cells by C4BP did not involve CD40L
but required CD40 (Figures 3–5). C4BP failed to induce Engagement of CD40 by C4BP triggered signaling
pathways similar to those triggered by CD40L, specifi-detectable CD40L expression on B cells but did induce
the activation of PBMC from patients with CD40L defi- cally NFB and the MAP kinase p38. C4BP caused nu-
clear translocation of NFB and upregulated, in anciency. C4BP activation of B cells was dependent on
CD40 expression, because C4BP failed to induce activa- IKK/NEMO-dependent manner, the expression of A20,
bcl-xL, and c-myc genes, which are known to be up-tion of PBMC from a CD40-deficient patient.
Induction of IgE synthesis by C4BPIL-4 most likely regulated similarly following CD40L stimulation. Further
evidence for a role of NFB was provided by the obser-involved isotype switching rather than simply amplifica-
tion of IgE synthesis by previously switched B cells. vation that C4BP failed to induce proliferation, upregula-
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Figure 7. Immunohistochemical Detection of
C4BP in Human Tonsillar Tissue
Human tonsillar tissue sections (A and B)
were stained with anti-C4BP IgG, anti-C4BP
IgG adsorbed with C4BP (Adsorbed), anti-
CD40 mAb, IgG1 isotype control, anti-CD19,
anti-CD3, or biotin-PNA, detected by HRP de-
velopment with 3-amino-9-ethylcarbazole and
counterstained with hematoxylin. (A) and (B)
represent sequential sections from two differ-
ent tonsil specimens. A representative area
containing the same secondary follicle for
each section is shown.
tion of CD54 and CD86 surface expression, and IgE plasma C4BP, as only a small fraction of the total B
cells in the body are present in the circulation. It is alsoisotype switching in PBMC from two patients with IKK/
NEMO mutations (Figures 3–6). possible that circulating plasma proteins may compete
with CD40 on B cells for binding of C4BP. A potentialC4BP downregulated the expression of DAG kinase
 and p38, two genes that are downregulated following candidate is serum amyloid protein, SAP, which has
been reported to bind to the core region of C4BP (GarciaCD40 ligation in a p38-dependent manner (Figure 6E).
C4BP-induced downregulation was blocked by the p38 de Frutos et al., 1995). Further studies are needed to
characterize the nature of binding between CD40 andinhibitor SB203580, strongly suggesting that C4BP acti-
vated p38 in B cells. At 10 M, the inhibitor SB203580 C4BP, including examination of the potential role of oli-
gosaccharides that decorate CD40. Future studies willblocks 95% of p38 activity but also 15% of JNK activity
(Cuenda et al., 1995). Inhibition of JNK activity is unlikely focus on mapping the CD40 binding site on C4BP and
examining whether circulating B cells carry C4BP onto account for the C4BP effect since JNK inhibitors have
no effect of the expression on DAG kinase and p38 their surface.
We found that C4BP is selectively localized in the B(Dadgostar et al., 2002). SB203580 was recently found to
inhibit CD40-mediated IgE isotype switching in human B cell-rich secondary follicles of human tonsils (Figure 7).
The fact that C4BP was not detected in T cell-rich areascells (Brady et al., 2001; Zhang et al., 2002); thus, p38
activation by C4BP is also likely to be important for suggests that C4BP does not exude nonspecifically into
the extravascular space. The selective presence ofC4BP-mediated IgE isotype switching.
C4BP is abundant in the circulation where its level C4BP in B cell-rich areas suggests that it is either carried
on the surface of cells that transmigrate from the circula-(100–150 g/ml) exceeds by 5- to 8-fold the concentra-
tions we have used to activate B cells in vitro. Circulating tion and/or is produced locally in the secondary follicle.
Synthesis of C4BP in cultured monocytes treated withB cells may not be important targets for activation by
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clear cells (PBMC) were purified from donors by Ficoll-Hypaque-inflammatory cytokines or hydrocortisone has been pre-
Plus (Amersham Biosciences, Piscataway, NJ) density gradient cen-viously described (Lappin and Whaley, 1990; Moffat and
trifugation (Jabara et al., 1990). B cells were prepared from PBMCsTack, 1992). This leads to the speculation that C4BP is
by purification with the StemSep B Cell Purification Kit (Stem Cell
specifically produced at sites of inflammation and could Technologies, Vancouver, BC Canada). All cells were maintained in
act to augment B cell immune responses. Further stud- RPMI 1640 supplemented with 10% fetal calf serum (FCS; Hyclone,
Logan, UT).ies are needed to determine whether C4BP is synthe-
sized locally in human tonsils and its cellular source.
Naive IgDCD38 B cells in lymphoid tissues are acti- Purification and Microsequencing of p23 Protein
vated in extrafollicular areas by contact with CD40L The purification and sequencing of p23 was previously described
(Morio et al., 1995). Sequences obtained were not originally re-T cells and antigen and subsequently migrate to the
ported, and it was described that no significant matches were founddark zone of germinal centers where they become
in the National Biomedical Research data bank. Recent searchesIgDCD38CD77 centroblasts that undergo SHM (Liu
of the SwissProt database were required to identify similarities toet al., 1996). Centroblasts mature into IgDCD38CD77
sequences in bovine and human C4BP, which were cloned subse-
centrocytes that undergo CSR and then differentiate quent to the original report. The sequences are now reported in
into IgDCD38 memory cells or plasma cells. CD40 Figure 1A.
ligation is thought to play an important role in B cell
survival, proliferation, and differentiation throughout this
Coimmunoprecipitation of p23 with CD40
process. This is suggested by the observations that BJAB cells (25  106 cells per precipitation) were lysed on ice,
CD40 ligation rescues isolated centroblasts from rapid precleared with normal mouse or rabbit serum coupled to protein
G-sepharose beads (Amersham Biosciences, Piscataway, NJ) asin vitro apoptosis and is important for SHM during the
previously described (Morio et al., 1995). Exogenous C4BP wasantibody response to T dependent-antigens, which oc-
added at this stage at 20 g/ml to cell lysates in the indicatedcurs predominantly in centroblasts (Chu et al., 1995;
experiments. Immunoprecipitations of CD40 with the appropriateCleary et al., 1995). However, CD40L is virtually unde-
mouse antibodies coupled to protein G-sepharose beads were
tectable in the dark zone of tonsil secondary follicles washed with lysis buffer four times and separated by SDS-PAGE
where centroblasts reside (Vyth-Dreese et al., 1995). The before transfer to nitrocellulose (Biorad, Hercules, CA). Blots were
probed with anti-CD40 (626.1) or anti-p23 antiserum followed bycolocalization of C4BP, PNA, and CD40 in tonsil second-
anti-rabbit or anti-mouse IgG-HRP conjugates and developed byary follicles suggests that CD40 signaling by C4BP in B
enhanced chemiluminescence (Amersham Biosciences).cells subsequent to their activation by CD40L T cells
in extrafollicular areas may be important for their survival
in germinal centers. Studies in C4BP-deficient mice are In Vitro C4BP Binding Assays
Purified murine IgG2a (Sigma, St. Louis, MO) or sCD40:Ig at 1 gneeded to test this hypothesis.
coupled to Protein G Sepharose beads and C4BP at 20 g was
combined in 100 l RPMI-1640 containing 0.5%BSA on ice. TheExperimental Procedures
complexed proteins were isolated by centrifugation and washed
four times with binding buffer. Precipitated proteins were blottedReagents
and probed with rabbit anti-C4BP IgG and anti-rabbit IgG-HRP con-The 626.1 anti-CD40 IgG1 mAb was a gift of Dr. S.M. Fu (University
jugates and developed by enhanced chemiluminescence.of Virginia). MOPC21 IgG1 mAb (Sigma), 3B12 anti-MHC Class II
IgG2a mAb (Spertini et al., 1992), and rabbit anti-human C4BP IgG
(Blom et al., 1999) are as described. The rabbit anti-p23 antiserum Flow Cytometry
was generated against the sequence LSVEKDQYVSPETVTVR (Morio C4BP binding to cell surfaces was detected using biotinylated C4BP
et al., 1995). Human C4Bp71 and C4BP6 are as previously de- and streptavidin (SA) conjugated to phycoerythrin (PE) (BD Biosci-
scribed (Blom et al., 2001a). Soluble huCD40L:muCD8 (sCD40L) and ences). Purified C4BP was conjugated to biotin with No-Weigh Bio-
CD40:Ig (sCD40) fusion proteins were purchased from Ancell Corp tin-NHS (Pierce Biotechnology, Rockford, IL). Cells were washed
(Bayview, MN). The anti-human IgE ELISA mAbs 4.15 and 7.12 were twice in RPMI-1640 supplemented with 0.5% BSA and 0.01% so-
a gift from A. Saxon. The p38 inhibitor, SB203580, was obtained dium azide and then resuspended at a concentration of 1  106
from Calbiochem (San Diego, CA). cells/ml. 1  105 cells were then incubated with 100 l biotinylated
C4BP (20 g/ml) on ice, washed, and incubated with SA-PE. Follow-
Cells Lines ing additional washes, the cells were fixed with 2% paraformalde-
The human B cell lines Raji, Ramos, and Daudi and the human T cell hyde and analyzed.
lines Jurkat 6.1 and HUT-78 were obtained from American Tissue CD40, CD19, and CD3 surface expression was determined by
Culture Collection. The EBV-negative Burkitt lymphoma B cell line incubating the cells for 30 min on ice with the appropriate fluorescein
BJAB was obtained from E. Kieff (Harvard Medical School). isothiocyanante (FITC) or PE-conjugated mAbs (BD Biosciences).
Events were analyzed using a FACScalibur flow cytometer.
Binding of sCD40L to B cells was examined using a soluble humanPatient and Control Blood Samples
The CD40-deficient patient with a point mutation leading to exon 5 biotinylated and unlabeled CD40L:muCD8 fusion protein followed
by SA-PE or hamster anti-mouse CD8 PE (BD Biosciences). Blockingdeletion were previously described (Ferrari et al., 2001). HED pa-
tients and X-HIgM patients have been confirmed to carry mutations experiments were performed by staining BJAB cells with 1 g/ml
biotinylated huCD40L:CD8 fusion protein or 20 g/ml biotinylatedin the IKK/NEMO (C417→Y in Exon 4 for IKK/NEMO #1 and
T1249→C in Exon 10 in IKK/NEMO #2) and CD40L (C590→A  human C4BP followed by SA-PE. Preincubation for 20 min of 20
g/ml or 100 g/ml of human IgM (Sigma), unlabeled CD40L:CD8deletion of C589 in CD40L #1 and 424–429 in-frame deletion in
CD40L #2) genes (Orange et al., 2002; Ramesh et al., 1993; Chu or unlabeled C4BP was used to block binding of biotinylated
CD40L:CD8 or biotinylated C4BP, respectively.et al., 1995; our unpublished data). HED-ID and X-HIgM patients
displayed normal levels of CD40 on their surface as assessed by To examine CD40-mediated upregulation of CD54 and CD86 ex-
pression, 1  106 PBMCs or purified B cells in medium containingFACS analysis. All patients were evaluated with parental/patient
consent. The Children’s Hospital Committee on Clinical Investiga- 10% FCS were stimulated with sCD40L (0.5 g/ml) or C4BP (20 g/
ml) for 36 hr. After culture, the cells were stained with anti-ICAM1-tion (CH-CCI) approved all studies.
Blood samples were obtained from patients and healthy control PE or anti-CD86-PE plus anti-CD20-FITC (BD Biosciences) and ana-
lyzed.adults with no recent history of illness. Peripheral blood mononu-
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Accepted: April 2, 2003PBMCs or purified B cells were stimulated in the presence of C4BP
or sCD40L alone, IL-4 (5 ng/ml, R&D Systems, Minneapolis, MN) or Published: June 17, 2003
IL-4 in combinations with C4BP or sCD40L. For experiments requir-
ing isolation of RNA, 1  106 cells were stimulated for 6, 12, 24, or References
72 hr. 10 M of p38 inhibitor SB203580 was preincubated in culture
supernatants. Stimulation for controls was done with IL-2 (1000 Aicher, A., Shu, G.L., Magaletti, D., Mulvania, T., Pezzutto, A., Crax-
U/ml; R&D Systems), IL-4, and PHA (10 g/ml; Sigma). ton, A., and Clark, E.A. (1999). Differential role for p38 mitogen-
activated protein kinase in regulating CD40-induced gene expres-
sion in dendritic cells and B cells. J. Immunol. 163, 5786–5795.Proliferation and In Vitro IgE Synthesis
PBMCs or B cells (3  105/well) were cultured in 96-well plates with Banchereau, J., Bazan, F., Blanchard, D., Briere, F., Galizzi, J.P.,
sCD40L (0.5 g/ml), recombinant human IL-4 (5 ng/ml), CD40IL-4, van Kooten, C., Liu, Y.J., Rousset, F., and Saeland, S. (1994a). The
or EBVIL-4 (Jabara et al., 2001) in RPMI10% FCS. Proliferation CD40 antigen and its ligand. Annu. Rev. Immunol. 12, 881–922.
was assayed 4 days for 3H-thymidine incorporation (Jabara et al., Banchereau, J., Briere, F., Liu, Y.J., and Rousset, F. (1994b). Molecu-
1991). For detection of IgE synthesis, supernatants were harvested lar control of B lymphocyte growth and differentiation. Stem Cells
at day 14 (days 28–35 for EBVIL-4), and IgE was assayed by ELISA 12, 278–288.
(Jabara et al., 1991).
Berberich, I., Shu, G.L., and Clark, E.A. (1994). Cross-linking CD40
on B cells rapidly activates nuclear factor-kappa B. J. Immunol. 153,
RT-PCR 4357–4366.
RT-PCR was performed on Superscript II (Invitrogen Life Sciences, Berggard, K., Johnsson, E., Mooi, F.R., and Lindahl, G. (1997). Bor-
Carlsbad, CA) generated cDNA that was prepared from Trizol (In- detella pertussis binds the human complement regulator C4BP: role
vitrogen Life Sciences) isolated RNA. Detection of the CD40-regu- of filamentous hemagglutinin. Infect. Immun. 65, 3638–3643.
lated genes Bcl-xL, A20, AID, DAG kinase , and CGLT by RT-PCR
Blom, A.M., Webb, J., Villoutreix, B.O., and Dahlback, B. (1999). Awere performed as previously described (Jabara et al., 2002; Zhang
cluster of positively charged amino acids in the C4BP alpha-chainet al., 2002). Detection of human c-myc and p38 by RT-PCR em-
is crucial for C4b binding and factor I cofactor function. J. Biol.ployed the 5GGGCACAGCGTCTGCTCCAC plus 3CACCAGATGT
Chem. 274, 19237–19245.TCGAAGCTGTTCGAG and 5CTCAGGATTCTGGATTTTGGGCT
Blom, A.M., Kask, L., and Dahlback, B. (2001a). Structural require-GGC plus 3CTTGGTCAAGGGGTGGTGGCAC primers, respectively.
ments for the complement regulatory activities of C4BP. J. Biol.Samples were diluted, and PCR was performed to detect the
Chem. 276, 27136–27144.housekeeping gene GAPDH for normalization of cDNA and to deter-
mine the linear range of the assays. Dilutions were performed on Blom, A.M., Rytkonen, A., Vasquez, P., Lindahl, G., Dahlback, B.,
all samples to ensure linearity of the reactions. and Jonsson, A.B. (2001b). A novel interaction between type IV
pili of Neisseria gonorrhoeae and the human complement regulator
C4B-binding protein. J. Immunol. 166, 6764–6770.DC-PCR
Blom, A.M., Kask, L., and Dahlback, B. (2003). CCP1–4 of the C4b-DNA isolation, S→S deletional switch recombination (CDC-PCR),
binding protein -chain are required for factor I mediated cleavageand control -globin DC-PCR was performed as previously de-
of C3b. Mol. Immunol. 39, 547–556.scribed (Weckert et al., 2000). DNA was isolated from the cell cul-
tures after 14 days. BglII was used to digest the isolated genomic Brady, K., Fitzgerald, S., Ingvarsson, S., Borrebaeck, C.A., and Moy-
DNA prior to circularization with T4 DNA ligase. nagh, P.N. (2001). CD40 employs p38 MAP kinase in IgE isotype
switching. Biochem. Biophys. Res. Commun. 289, 276–281.
Electrophoretic Mobility Shift Assay (EMSA) for NFB Calderhead, D.M., Kosaka, Y., Manning, E.M., and Noelle, R.J.
A double-stranded consensus NFB oligonucleotide (Promega) was (2000). CD40–CD154 interactions in B-cell signaling. Curr. Top. Mi-
5-end-labeled with [32P]-ATP (Perkin-Elmer Life Sciences) and crobiol. Immunol. 245, 73–99.
purified by PAGE. Nuclear extracts were prepared and EMSA was Castigli, E., Alt, F.W., Davidson, L., Bottaro, A., Mizoguchi, E., Bhan,
performed essentially as described (Jabara et al., 2002). A.K., and Geha, R.S. (1994). CD40-deficient mice generated by re-
combination-activating gene-2-deficient blastocyst complementa-
tion. Proc. Natl. Acad. Sci. USA 91, 12135–12139.Immunohistochemical Analysis
Cryo-preserved human tonsil tissue samples were obtained from Challa, A., Pound, J.D., Armitage, R.J., and Gordon, J. (1999). Epi-
the tissue bank of the Department of Pathology at Massachusetts tope-dependent synergism and antagonism between CD40 antibod-
General Hospital (Boston). 4-m-thick frozen sections were air dried ies and soluble CD40 ligand for the regulation of CD23 expression
for 20 min and stained by the avidin-biotin complex method (Mizo- and IgE synthesis in human B cells. Allergy 54, 576–583.
guchi et al., 1997). Fixed sections were incubated with rabbit anti- Chu, Y.W., Marin, E., Fuleihan, R., Ramesh, N., Rosen, F.S., Geha,
C4BP IgG, anti-CD19, anti-CD3, and anti-CD40 (626.1) at 1:100 dilu- R.S., and Insel, R.A. (1995). Somatic mutation of human immuno-
tion for 1 hr. C4BP pre-adsorbed to anti-C4BP IgG was used as a globulin V genes in the X-linked HyperIgM syndrome. J. Clin. Invest.
negative control. Specimens were incubated with biotinylated goat 95, 1389–1393.
anti-rabbit Ig (Vector Laboratories), biotinylated PNA (Vector Labo-
Cleary, A.M., Fortune, S.M., Yellin, M.J., Chess, L., and Lederman,ratories), or biotinylated horse anti-mouse Ig (Vector Laboratories)
S. (1995). Opposing roles of CD95 (Fas/APO-1) and CD40 in theat 1:200 dilution followed by avidin-HRP (Dako, Carpinteria, CA).
death and rescue of human low density tonsillar B cells. J. Immunol.She specimens were developed in a solution of 3-amino-9-ethylcar-
155, 3329–3337.bazole (Aldrich Chemical Co., Milwaukee, WI) and counterstained
Cooper, S.T., and Attie, A.D. (1992). Pig apolipoprotein R: a newwith hematoxylin before Glycergel mounting (Dako).
member of the short consensus repeat family of proteins. Biochem-
istry 31, 12328–12336.
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